Search for: "Cubist Pharmaceuticals"
Idera Pharmaceuticals Announces Management Appointments and Promotion
HSMN NewsFeed,
7 Apr 2010:
Biopharmaceuticals, Personnel
[Idera Pharmaceuticals]
|
Cubist Pharmaceuticals to Acquire Calixa Therapeutics
HSMN NewsFeed,
14 Dec 2009:
Biopharmaceuticals, Mergers & Acquisitions
[Cubist Pharmaceuticals, Calixa Therapeutics]
|
Trial Date Set for CUBICIN(R) Patent Litigation
HSMN NewsFeed,
11 Dec 2009:
Biopharmaceuticals, Generics, Litigation
[Cubist Pharmaceuticals, Teva Pharmaceutical, daptomycin, CUBICIN]
|
Dyax Announces FDA Approval of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older
HSMN NewsFeed,
1 Dec 2009:
Biopharmaceuticals, FDA
[Dyax, KALBITOR, ecallantide, hereditary angioedema]
|
aTyr Pharma Raises an Additional $12 Million
HSMN NewsFeed,
28 Jul 2009:
Biopharmaceuticals, Venture Capital
[aTyr Pharma]
|
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
HSMN NewsFeed,
13 May 2009:
Biopharmaceuticals, Personnel
[Follica]
|
Archemix Appoints Ken Bate as President and Chief Executive Officer
HSMN NewsFeed,
6 May 2009:
Biopharmaceuticals, Personnel
[Archemix, aptamer]
|
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer
HSMN NewsFeed,
8 Apr 2009:
Biopharmaceuticals, Personnel
[Cerulean Pharma]
|
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
HSMN NewsFeed,
10 Feb 2009:
Biopharmaceuticals, Ophthalmology
[Dyax, ovea Pharmaceuticals, DX-88]
|
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
HSMN NewsFeed,
4 Feb 2009:
Biopharmaceuticals, FDA
[Dyax, DX-88, ecallantide, hereditary angioedema]
|
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed,
8 Jan 2009:
Biopharmaceuticals, Neurology, Venture Capital, Personnel
[Satori Pharmaceuticals, Alzheimer's disease, Parkinson's disease]
|
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
HSMN NewsFeed,
6 Jan 2009:
Biopharmaceuticals, Personnel
[ARIAD Pharmaceuticals]
|
Cubist Names Santosh J. Vetticaden as SVP, Clinical Development and Chief Medical Officer
HSMN NewsFeed,
2 Dec 2008:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals]
|
Microfabrica Secures $22.5 Million Funding to Grow Its Medical Device Business
HSMN NewsFeed,
4 Sep 2008:
Devices, Venture Capital
[Microfabrica Inc]
|
Follica Announces $11M in New Financing and Expanded Team
HSMN NewsFeed,
12 Aug 2008:
Devices, Personnel, Venture Capital
[Follica]
|
Dyax Corp. Announces the Appointment of George Migausky as Chief Financial Officer
HSMN NewsFeed,
7 Aug 2008:
Biopharmaceuticals, Personnel
[Dyax]
|
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
HSMN NewsFeed,
2 Jul 2008:
Biopharmaceuticals
[Cubist Pharmaceuticals, AstraZeneca, MERREM, meropenem, antibiotic]
|
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
HSMN NewsFeed,
3 Jun 2008:
Biopharmaceuticals
[Sepracor, Oryx Pharmaceuticals, Arrow Group]
|
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
HSMN NewsFeed,
1 May 2008:
Biopharmaceuticals, Mergers & Acquisitions
[Sepracor, Oryx Pharmaceuticals, Arrow Group]
|
Dyax Corp. and Cubist Pharmaceuticals, Inc. Sign Development and Commercialization Agreement for DX-88 Surgical Indications
HSMN NewsFeed,
24 Apr 2008:
Biopharmaceuticals
[Dyax, Cubist Pharmaceuticals, DX-88]
|
Cubist Pharmaceuticals Names Steven C. Gilman, Ph.D., as Senior Vice President, Discovery and Non-Clinical Development and Chief Scientific Officer
HSMN NewsFeed,
12 Feb 2008:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals]
|
Pervasis Therapeutics Closes Additional $9.75 Million in Financing
HSMN NewsFeed,
15 Jan 2008:
Regenerative Medicine, Venture Capital
[Pervasis Therapeutics, Vascugel, blood vessel repair]
|
Cubist Pharmaceuticals Acquires Illumigen Biosciences
HSMN NewsFeed,
26 Dec 2007:
Biopharmaceuticals, Mergers & Acquisitions
[Cubist Pharmaceuticals, Illumigen Biosciences]
|
Lev Pharmaceuticals Expands Senior Management Team
HSMN NewsFeed,
14 Nov 2007:
Biopharmaceuticals, Personnel
[Lev Pharmaceuticals, Matt Duffy, Bart Jones, Joe Truitt]
|
Dyax Announces the Appointment of William Pullman as Executive Vice President and Chief Development Officer
HSMN NewsFeed,
31 Oct 2007:
Biopharmaceuticals, Personnel
[Dyax]
|
Cubist Pharmaceuticals Announces Exclusive Option to Acquire Illumigen Biosciences
HSMN NewsFeed,
16 Oct 2007:
Biopharmaceuticals, Mergers & Acquisitions
[Cubist Pharmaceuticals, Illumigen Biosciences, Hepatitis C]
|
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed,
24 Sep 2007:
Biopharmaceuticals, Personnel
[Shire plc, Human Genetic Therapies]
|
Phreesia Secures $10.25M Series B Funding
HSMN NewsFeed,
17 Sep 2007:
Devices, Venture Capital
[Phreesia]
|
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
HSMN NewsFeed,
6 Sep 2007:
Biopharmaceuticals, Regulatory
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
Cubist Pharmaceuticals Creates COO Position, Adds Scientific Advisory Board
HSMN NewsFeed,
28 Aug 2007:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
Positive Opinion for Expanded Label of CUBICIN Received from European Regulatory Authority; Decision Expected This September
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, Regulatory
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
Solace Pharmaceuticals Raises $15M in Series A Financing; Names Senior Pfizer Executive as CEO
HSMN NewsFeed,
1 May 2007:
Biopharmaceuticals, Personnel, Venture Capital
[Solace Pharmaceuticals]
|
Aeris Therapeutics Strengthens Management Team
HSMN NewsFeed,
16 Apr 2007:
Devices, Drug Delivery, Personnel
[Aeris Therapeutics, Biologic Lung Volume Reduction]
|
Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc.
HSMN NewsFeed,
22 Mar 2007:
Biopharmaceuticals, Licensing
[Cubist Pharmaceuticals, Merck, Banyu Pharmaceutical, CUBICIN, daptomycin]
|
Vidacare Announces Director of Sales Operations, Bart P. Jones
HSMN NewsFeed,
6 Mar 2007:
Devices, Personnel
[Vidacare, EZ-IO]
|
Kenneth M. Bate Named CEO of NitroMed
HSMN NewsFeed,
22 Jan 2007:
Biopharmaceuticals, Personnel
[NitroMed]
|
Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in China to AstraZeneca
HSMN NewsFeed,
4 Dec 2006:
Biopharmaceuticals, Licensing
[Cubist Pharmaceuticals, AstraZeneca, CUBICIN, daptomycin]
|
Cubist Pharmaceuticals Appoints Martin Soeters to Its Board of Directors
HSMN NewsFeed,
27 Sep 2006:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals]
|
Avera Pharmaceuticals Names Dinu Sen Chief Executive Officer
HSMN NewsFeed,
14 Sep 2006:
Biopharmaceuticals, Personnel
[Avera Pharmaceuticals]
|
The New England Journal of Medicine Publishes Results of Cubist's Landmark Study of Staphylococcus Aureus Blood Stream Infections
HSMN NewsFeed,
16 Aug 2006:
Biopharmaceuticals
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
IDM Pharma Appoints Sylvie Gregoire, Pharm. D., as Executive Chair of the Board of Directors
HSMN NewsFeed,
15 Aug 2006:
Biopharmaceuticals, Personnel
[IDM Pharma]
|
XOMA Suspends HepeX-B(TM) Work Following Cubist Decision
HSMN NewsFeed,
28 Jul 2006:
Biopharmaceuticals
[XOMA, Cubist Pharmaceuticals, HepeX-B, hepatitis B]
|
XTL Biopharmaceuticals, Ltd. Announces Managerial Change
HSMN NewsFeed,
6 Jul 2006:
Biopharmaceuticals, Personnel
[XTL Biopharmaceuticals]
|
Cubist Pharmaceuticals Names William Pullman as Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
7 Jun 2006:
Biopharmaceuticals, Personnel
[Cubist Pharmaceuticals]
|
Life Science Angels Invests in NeuroHealing Pharmaceuticals
HSMN NewsFeed,
5 Apr 2006:
Biopharmaceuticals, Venture Capital
[Life Science Angels, NeuroHealing Pharmaceuticals]
|
Cubist Pharmaceuticals Has Submitted Response to FDA Approvable Letter Received on Friday
HSMN NewsFeed,
27 Mar 2006:
Biopharmaceuticals, FDA
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
FDA Issues Approvable Letter for CUBICIN sNDA
HSMN NewsFeed,
24 Mar 2006:
Biopharmaceuticals, FDA
[Cubist Pharmaceuticals, CUBICIN, daptomycin]
|
Boston Life Sciences, Inc. Announces Appointment of Senior Vice President, Regulatory Affairs and Quality
HSMN NewsFeed,
5 Jan 2006:
Biopharmaceuticals, Personnel
[Boston Life Sciences]
|
XTL Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
HSMN NewsFeed,
3 Jan 2006:
Biopharmaceuticals, Personnel
[XTL Biopharmaceuticals]
|
|
|
Public
Feeds 
Full text >>
